Rephonic
Artwork for Community Health Media

Community Health Media

Community Health Media
Her2-Positive Breast Cancer
Trastuzumab Deruxtecan
Breast Cancer
ESR1 Mutation
Her2-Positive Metastatic Breast Cancer
Destiny Breast 11
Trastuzumab Deruxtecan (TDXD)
Destiny-Breast11
Neoadjuvant Therapy
Serena 6
CTDNA
Antibody Drug Conjugates
Destiny-Breast05
Trastuzumab Deruxtecan (t-Dxd)
Cdk4-6 Inhibitors
Metastatic Triple-Negative Breast Cancer
Dato-Dxd
Hepatocellular Carcinoma
Destiny Breast 05
Endocrine Therapy

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences. We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferen... more

PublishesDailyEpisodes66Foundeda year ago
Number of ListenersCategories
Health & FitnessMedicine

Listen to this Podcast

Artwork for Community Health Media

Latest Episodes

A new era in HER2-positive metastatic breast cancer is here.Dr. Jason Mouabbi, Dr. Ruta Rao, and Dr. Mark Pegram break down the groundbreaking DESTINY-Breast09 trial and discuss how trastuzumab deruxtecan (T-DXd) plus pertuzumab is redefining first-l... more

Can we improve outcomes by changing treatment before radiographic progression occurs?

In this in-depth discussion, Dr. Anne O'Dea and Dr. Mabel Mardones explore how the SERENA-6 trial is reshaping the management of HR-positive, HER2-negative metasta... more

HER2-positive breast cancer treatment is evolving rapidly. With FDA approvals from DESTINY-Breast11 and DESTINY-Breast05, when should clinicians incorporate trastuzumab deruxtecan (T-DXd) into practice—and how should it be used across early-stage and... more

The first-line treatment landscape for metastatic triple-negative breast cancer is changing rapidly.

Dr. Neil Iyengar, Dr. Joyce O'Shaughnessy, and Dr. Ana Garrido-Castro discuss how ADCs are reshaping frontline TNBC care and what the latest clinica... more

Key Facts

Accepts Guests
Contact Information
Podcast Host
Number of Listeners
Find out how many people listen to this podcast per episode and each month.

Similar Podcasts

People also subscribe to these shows.

Breast Cancer Conversations
Breast Cancer ConversationsSurvivingBreastCancer.org

Recent Guests

Anne O'Dea
Breast medical oncologist
University of Kansas Cancer Center
Episode: Dr. Anne O'Dea & Dr. Mabel Mardones - SERENA-6 & ctDNA-Guided Therapy in mBC
Mabel Mardones
Breast medical oncologist
Rocky Mountain Cancer Centers; Sarah Cannon Research Institute
Episode: Dr. Anne O'Dea & Dr. Mabel Mardones - SERENA-6 & ctDNA-Guided Therapy in mBC
Rena Callahan
Breast medical oncologist at UCLA
UCLA
Episode: Dr. Rena Callahan & Dr. Aditya Bardia - Integrating T-DXd in HER2+ Breast Cancer: DB11, DB05 & DB09
Joyce O'Shaughnessy
Breast medical oncologist
Baylor University Medical Center, Texas Oncology, Sarah Cannon Research Institute
Episode: Dr. Neil Iyengar, Dr. Joyce O'Shaughnessy, & Dr. Ana Garrido-Castro - Evolving ADCs in 1L mTNBC
Ana Garrido-Castro
Breast medical oncologist
Dana-Farber Cancer Institute
Episode: Dr. Neil Iyengar, Dr. Joyce O'Shaughnessy, & Dr. Ana Garrido-Castro - Evolving ADCs in 1L mTNBC
Fengting Yan
Physician from Fred Hutch Cancer Center, Seattle
Fred Hutch Cancer Center
Episode: Dr. Jason Mouabbi, Dr. Fenting Yan, & Dr. Paolo Tarantino - First-Line T-DXd in HER2+ mBC
Paolo Tarantino
Physician from Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Episode: Dr. Jason Mouabbi, Dr. Fenting Yan, & Dr. Paolo Tarantino - First-Line T-DXd in HER2+ mBC
Dr. Ryan Rader
Assistant Professor specializing in breast cancer
University of Kansas
Episode: Dr. Megan Kruse, Dr. Ryan Rader, & Dr. Praveen Vikas - DB11 & DB05 Change HER2+ Care
Dr. Praveen Vikas
Associate Professor focusing on breast cancer
University of Iowa
Episode: Dr. Megan Kruse, Dr. Ryan Rader, & Dr. Praveen Vikas - DB11 & DB05 Change HER2+ Care

Hosts

Neil Iyengar
Host of the discussion and session leadership across episodes.
Ghassan Abou-Alfa
Host of the session and clinical strategy discussions.
Ursa Brown-Glaberman
Host of the discussion (medical oncologist) with focus on breast oncology.
Karthik Giridhar
Host of the discussion (Breast Medical Oncologist).

Chart Rankings

How this podcast ranks in the Apple Podcasts, Spotify and YouTube charts.

Talking Points

Recent interactions between the hosts and their guests.

Dr. Gregory Vidal & Dr. Nusayba Bagegni - Is HER2+ Metastatic Breast Cancer Curable? DESTINY-Breast09, Patina & What Comes Next
Q: How do you approach sequencing after DB09, Patina, or HER2 Climb in real-world practice, and what factors influence your choices?
Sequencing is increasingly nuanced and individualized. Factors include prior CNS involvement, disease-free interval, hormone receptor status, tolerability, and patient preferences. There is consideration of re-challenge with TDXD in some cases, use of HER2 Climb (with tucatinib) in second line, and the potential integration of CDK4/6 inhibitors or antibody-drug conjugates in later lines depending on prior exposure and toxicity history.
Dr. Gregory Vidal & Dr. Nusayba Bagegni - Is HER2+ Metastatic Breast Cancer Curable? DESTINY-Breast09, Patina & What Comes Next
Q: What endpoints are considered most important when designing new trials in this space, given the observed long-term responses?
Key endpoints include complete response rates, durability of response, and quality of life, in addition to traditional progression-free and overall survival. There is a focus on achieving deeper responses and translating them into meaningful, sustained disease control while monitoring and minimizing toxicities like ILD.
Dr. Gregory Vidal & Dr. Nusayba Bagegni - Is HER2+ Metastatic Breast Cancer Curable? DESTINY-Breast09, Patina & What Comes Next
Q: What is the current understanding of first-line therapy for HER2-positive metastatic breast cancer in light of DESTINY-Breast09, and how does it compare to the Cleopatra regimen?
The first-line standard has been taxane plus trastuzumab and pertuzumab with continuation; DESTINY-Breast09 suggests adding TDXD can significantly extend progression-free survival in selected patients, particularly those with favorable biomarker profiles, while maintaining tolerability. This has sparked consideration of induction strategies and targeted endocrine or CDK4/6 combinations in specific subgroups, and may lead to more nuanced, biomarker-driven decision-making rather than a uniform approach for all patients.
Drs. Alvarez, Dr. Mazo-Canola & Dr. Sandoval-Leon - The Future of Breast Cancer Treatment & Precision Oncology
Q: ¿Cómo explican los subtipos de cáncer de mama y el approach inicial para cada uno?
Se destacan tres grandes categorías (HR+/HER2-, HER2+, y triple negativo) y la importancia de clasificar para decidir la secuencia: cirugía, quimioterapia, y terapias dirigidas según el subtipo y estadio.
Dr. Hope Rugo & Dr. Rebecca Shatsky - Earlier ESR1 Detection & Oral SERDs in Metastatic Breast Cancer
Q: How do you decide when to test for ESR1 mutations in a metastatic HR-positive breast cancer patient?
Baseline testing is important for patients with prior aromatase inhibitor exposure, and serial CTDNA monitoring every two to three months in trials informs timing for switching therapies, with a leaning toward earlier testing to guide timely changes rather than waiting for radiographic progression.

Audience Metrics

Listeners, social reach, demographics and more for this podcast.

Listeners per Episode
Gender Skew
Location
Interests
Professions
Age Range
Household Income
Social Media Reach

Frequently Asked Questions About Community Health Media

What is Community Health Media about and what kind of topics does it cover?

This series centers on deep-dive conversations with leading clinicians and researchers in oncology and gastroesophageal cancers, often featuring roundtables and expert panels that unpack the latest trial data, treatment sequencing, and real-world implementation. Episodes frequently explore antibody-drug conjugates, targeted therapies, biomarker-driven decision-making, toxicity management, and practical considerations for coordinating multidisciplinary care across academic centers and community practices. A standout aspect is the consistent emphasis on translating complex trial results into actionable guidance for clinicians, with an underlying focus on patient-centered decision-making and real-world realities such as access, sequencing, and... more

Where can I find podcast stats for Community Health Media?

Rephonic provides a wide range of podcast stats for Community Health Media. We scanned the web and collated all of the information that we could find in our comprehensive podcast database. See how many people listen to Community Health Media and access YouTube viewership numbers, download stats, audience demographics, chart rankings, ratings, reviews and more.

How many listeners does Community Health Media get?

Rephonic provides a full set of podcast information for three million podcasts, including the number of listeners. View further listenership figures for Community Health Media, including podcast download numbers and subscriber numbers, so you can make better decisions about which podcasts to sponsor or be a guest on. You will need to upgrade your account to access this premium data.

What are the audience demographics for Community Health Media?

Rephonic provides comprehensive predictive audience data for Community Health Media, including gender skew, age, country, political leaning, income, professions, education level, and interests. You can access these listener demographics by upgrading your account.

How many subscribers and views does Community Health Media have?

To see how many followers or subscribers Community Health Media has on Spotify and other platforms such as Castbox and Podcast Addict, simply upgrade your account. You'll also find viewership figures for their YouTube channel if they have one.

Which podcasts are similar to Community Health Media?

These podcasts share a similar audience with Community Health Media:

1. Breast Cancer Conversations

How many episodes of Community Health Media are there?

Community Health Media launched a year ago and published 66 episodes to date. You can find more information about this podcast including rankings, audience demographics and engagement in our podcast database.

How do I contact Community Health Media?

Our systems regularly scour the web to find email addresses and social media links for this podcast. We scanned the web and collated all of the contact information that we could find in our podcast database. But in the unlikely event that you can't find what you're looking for, our concierge service lets you request our research team to source better contacts for you.

Where can I see ratings and reviews for Community Health Media?

Rephonic pulls ratings and reviews for Community Health Media from multiple sources, including Spotify, Apple Podcasts, Castbox, and Podcast Addict.

View all the reviews in one place instead of visiting each platform individually and use this information to decide if a show is worth pitching or not.

How do I access podcast episode transcripts for Community Health Media?

Rephonic provides full transcripts for episodes of Community Health Media. Search within each transcript for your keywords, whether they be topics, brands or people, and figure out if it's worth pitching as a guest or sponsor. You can even set-up alerts to get notified when your keywords are mentioned.

What guests have appeared on Community Health Media?

Recent guests on Community Health Media include:

1. Anne O'Dea
2. Mabel Mardones
3. Rena Callahan
4. Joyce O'Shaughnessy
5. Ana Garrido-Castro
6. Fengting Yan
7. Paolo Tarantino
8. Dr. Ryan Rader

To view more recent guests and their details, simply upgrade your Rephonic account. You'll also get access to a typical guest profile to help you decide if the show is worth pitching.

Find and pitch the right podcasts

We help savvy brands, marketers and PR professionals to find the right podcasts for any topic or niche. Get the data and contacts you need to pitch podcasts at scale and turn listeners into customers.
Try it free for 7 days